This company listing is no longer active
DSM-Firmenich Future Growth
Future criteria checks 4/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for DSM-Firmenich.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Chemicals earnings growth | 0% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | 31 May 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DSM2's forecast earnings growth (20.5% per year) is above the savings rate (0.2%).
Earnings vs Market: DSM2's earnings (20.5% per year) are forecast to grow faster than the German market (13.3% per year).
High Growth Earnings: DSM2's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: DSM2's revenue (11.1% per year) is forecast to grow faster than the German market (4.3% per year).
High Growth Revenue: DSM2's revenue (11.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DSM2's Return on Equity is forecast to be high in 3 years time